List of Excipients in Branded Drug TERBINAFINE HYDOCHLORIDE

Generic Drugs Containing TERBINAFINE HYDOCHLORIDE

Company	Ingredient	NDC	Excipient
Physicians Total Care Inc	terbinafine hydrochloride	54868-5794	CROSCARMELLOSE SODIUM
Physicians Total Care Inc	terbinafine hydrochloride	54868-5794	MAGNESIUM STEARATE
Physicians Total Care Inc	terbinafine hydrochloride	54868-5794	METHYLCELLULOSE
Physicians Total Care Inc	terbinafine hydrochloride	54868-5794	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in TERBINAFINE HYDOCHLORIDE?

# Of NDCs	Excipient
1	CROSCARMELLOSE SODIUM
1	MAGNESIUM STEARATE
1	METHYLCELLULOSE
1	SILICON DIOXIDE

Terbinafine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Terbinafine hydrochloride is a mature antifungal active with limited compound-level exclusivity and broad generic availability. Commercial value is shifting from the active ingredient to formulation performance, adherence, differentiated delivery, pediatric dosing, nail penetration, tolerability, and manufacturing efficiency. The strongest opportunities are topical products that improve residence time and delivery through the nail or skin, oral products with reliable dissolution and dose flexibility, and combination or device-enabled products that support adherence.

What is the pharmaceutical and regulatory profile of terbinafine hydrochloride?

Terbinafine hydrochloride is the hydrochloride salt of terbinafine, an allylamine antifungal that inhibits squalene epoxidase. It is used orally and topically for dermatophyte infections, including onychomycosis, tinea corporis, tinea pedis, tinea cruris, and tinea capitis.

Attribute	Commercial relevance
Active ingredient	Terbinafine hydrochloride
Therapeutic class	Allylamine antifungal
Principal oral dosage form	Immediate-release tablet
Principal topical forms	Cream, gel, spray, solution, aerosol and related semisolid systems
Oral reference product	Lamisil tablets
Common topical reference product	Lamisil AT and other terbinafine products
Primary mechanism	Squalene epoxidase inhibition
Key formulation issue	Low aqueous solubility and the need for effective skin or nail delivery
Main safety issue	Oral hepatotoxicity and drug-interaction risk
Regulatory status	Generic oral products approved in the United States; many topical products marketed over the counter or through national equivalents

Terbinafine hydrochloride is lipophilic and has limited water solubility. That profile supports membrane and keratin partitioning but creates formulation challenges for aqueous topical products and oral dissolution. The active is also a clinically relevant CYP2D6 inhibitor, which affects oral-product labeling and risk management. FDA labeling recommends evaluation for chronic or active liver disease before oral treatment and identifies hepatic injury as a clinically important risk.[1]

What excipients are used in terbinafine hydrochloride tablets?

Immediate-release tablets are the most established oral platform. Their commercial objective is consistent dissolution, mechanical robustness, low manufacturing cost and adequate stability.

Typical excipient functions include:

Excipient class	Examples used in oral solid-dose development	Function
Diluent	Lactose monohydrate, microcrystalline cellulose, calcium phosphate	Tablet mass and compressibility
Disintegrant	Sodium starch glycolate, crospovidone, croscarmellose sodium	Rapid tablet breakup
Binder	Povidone, hypromellose, pregelatinized starch	Granule and tablet strength
Glidant	Colloidal silicon dioxide	Powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Film coat	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Identification, handling and protection
Surfactant or wetting aid	Sodium lauryl sulfate or equivalent, where justified	Improved wetting and dissolution

The precise composition varies by manufacturer and strength. FDA-approved product labeling identifies inactive ingredients for each product, while DailyMed provides current labeling and product-specific formulation information.[1,2]

How should tablet excipients be selected?

For terbinafine hydrochloride, formulation development should begin with dissolution and powder-flow data rather than with a fixed excipient recipe. The main formulation risks are incomplete wetting, hydrophobic particle agglomeration, compression variability and sensitivity to lubricant concentration.

A practical strategy is:

1. Use microcrystalline cellulose or a comparable diluent to support direct compression or dry granulation.
2. Include a high-performance disintegrant to reduce dependence on rapid dissolution of the active.
3. Control magnesium stearate level and blending time because over-lubrication can reduce wetting and dissolution.
4. Use particle-size control or milling to improve blend uniformity.
5. Evaluate wet granulation only when direct compression cannot meet content-uniformity or mechanical-strength requirements.
6. Compare dissolution across pH conditions because terbinafine is a weak base and may show pH-dependent solubility.

A low-cost generic tablet generally has limited differentiation. The commercial advantage comes from stable supply, low reject rates, tablet robustness, dose flexibility and regulatory cleanliness rather than from a novel excipient system.

What excipients are used in terbinafine hydrochloride creams and topical products?

Topical terbinafine products require a balance between solubilization, skin partitioning, evaporation, sensory performance and preservative control. The active must leave the vehicle and partition into the stratum corneum without excessive crystallization.

Typical topical excipient categories include:

Excipient class	Examples	Formulation purpose
Solvent	Water, ethanol, propylene glycol, polyethylene glycol	Solubilization and spreading
Emollient	Isopropyl myristate, fatty alcohols, esters	Skin feel and active partitioning
Emulsifier	Sorbitan esters, polysorbates, glyceryl stearate	Emulsion stability
Thickener	Carbomer, cetyl alcohol, stearyl alcohol, hydroxyethylcellulose	Viscosity and residence time
Humectant	Propylene glycol, glycerol	Hydration and vehicle feel
Buffer or pH adjuster	Sodium hydroxide, citric acid, phosphate systems	pH control and stability
Preservative	Benzyl alcohol, phenoxyethanol, parabens or other approved systems	Microbial protection
Film former	Povidone, acrylate polymers, cellulose derivatives	Longer residence and reduced rub-off
Penetration enhancer	Glycols, fatty esters and selected surfactants	Skin delivery

Creams often provide the lowest development risk because the technology is established and manufacturing is straightforward. However, the product must maintain physical stability and avoid active precipitation during shelf life. A vehicle that initially solubilizes terbinafine can lose performance if water evaporates, pH changes or the active crystallizes.

Which topical excipient strategies have the strongest commercial potential?

The most attractive strategies are:

Low-irritancy solvent systems

Ethanol and propylene glycol can improve solubilization and penetration but may cause stinging, dryness or irritation. A lower-irritancy system using glycols, esters and controlled water activity can support use on fissured or inflamed skin.

Fast-drying sprays and solutions

Sprays can improve convenience and reduce hand contact. Volatile solvents support rapid drying, while film-forming polymers can retain terbinafine after solvent evaporation. The main risks are flammability, spray-pattern consistency, valve compatibility and variable dosing per actuation.

High-residence creams and gels

A structured emulsion or polymeric gel can reduce rub-off and extend skin contact. Commercial differentiation is strongest when the vehicle improves usability without increasing greasiness or residue.

Nail-delivery systems

Onychomycosis is a major unmet formulation challenge because the nail plate is a dense keratin barrier. A nail lacquer, film-forming solution, microemulsion or nanodispersion could create commercial value if it demonstrates greater nail penetration or reduced dosing burden. The technical risk is high because in vitro release does not necessarily predict delivery through infected human nail.

Barrier-compatible products

Products intended for interdigital tinea or cracked skin should minimize alcohol, fragrance and aggressive surfactants. This segment can support premium positioning based on tolerability and adherence.

What formulations are protected by terbinafine hydrochloride patents?

The original terbinafine compound and early Lamisil products are mature assets. In the United States, generic oral terbinafine tablets have been approved for years, and topical terbinafine products are widely marketed. The practical IP focus is therefore formulation and delivery rather than the basic active ingredient.

Potentially protectable subject matter includes:

• Specific solvent and cosolvent ratios.
• Particle-size distributions.
• Amorphous or co-processed terbinafine systems.
• Nail lacquers and film-forming vehicles.
• Spray compositions and metered-dose delivery systems.
• Sustained-release or depot systems.
• Combination products with corticosteroids, keratolytics or antibacterial agents.
• Pediatric granules or sprinkle formulations.
• Manufacturing processes that reduce polymorphic conversion or active crystallization.
• Packaging systems that control moisture, evaporation or dose delivery.

Patent value depends on claim breadth, written-description support, enablement, freedom to operate and whether the claims cover a commercially meaningful product. A patent that protects only a narrow excipient ratio may have limited defensive value if a generic manufacturer can use a different solvent, polymer or process.

How strong is the current patent estate for terbinafine hydrochloride?

The estate is best characterized as weak at the molecule level and potentially stronger at the product level.

IP category	Relative barrier	Commercial assessment
Original terbinafine compound	Low	Mature and subject to generic competition
Standard oral tablet	Low	Limited differentiation and multiple generic pathways
Conventional cream	Low to moderate	Formulation claims may exist, but design-around risk is high
Spray or solution	Moderate	Device, solvent and film-forming claims may provide narrower protection
Nail-delivery system	Moderate to high	Technical differentiation is possible, but clinical proof is required
Pediatric granules	Moderate	Dose flexibility and palatability can support product claims
Manufacturing process	Moderate	Relevant where crystallinity, impurity control or scale-up is difficult
Combination products	Variable	Depends on clinical, regulatory and jurisdictional claim scope

A current patent-by-patent freedom-to-operate opinion requires a live search of national patent registers and court records. Patent expiration should not be inferred from product availability alone. The FDA Orange Book primarily covers approved drug products with applicable patent and exclusivity information; many over-the-counter topical products are outside the same listing framework.[3]

When does terbinafine hydrochloride lose exclusivity?

Terbinafine hydrochloride has already passed the principal U.S. exclusivity period associated with the original oral product. Generic oral tablets are commercially established. The commercial question is no longer whether the active can face generic entry, but whether a new dosage form or delivery system can obtain independent protection.

FDA approval of a new terbinafine product may still support:

• New drug application exclusivity for a qualifying new formulation or indication.
• Pediatric exclusivity where statutory requirements are met.
• Orphan-drug exclusivity only if the product qualifies for an orphan indication.
• Regulatory protection linked to a new clinical use, formulation or delivery route.

These protections are distinct from patent rights. FDA Orange Book listings, approved labeling and exclusivity records should be reviewed separately from USPTO and international patent data.[3,4]

What is the Orange Book status of terbinafine hydrochloride?

Approved prescription oral terbinafine tablets are within the FDA’s approved-drug framework and may be associated with listed patents or exclusivity records depending on the specific reference product and reporting status. Generic applicants use the applicable ANDA pathway and may submit patent certifications, including Paragraph IV certifications, where listed patents remain relevant.

Consumer topical terbinafine products are often marketed under nonprescription frameworks and may not have the same Orange Book profile as prescription tablets. The status of a specific product must be verified by application number, dosage form, sponsor and current FDA listing.[3]

Which companies are challenging terbinafine hydrochloride products?

The generic market includes multiple manufacturers and contract suppliers of terbinafine hydrochloride tablets and topical products. Competition is generally based on:

• API cost and supply continuity.
• Tablet and tube manufacturing cost.
• Approval status by strength and dosage form.
• Retail distribution.
• Private-label and store-brand relationships.
• Ability to support multiple pack sizes.
• Product appearance and labeling compliance.

For mature products, Paragraph IV litigation is usually less commercially important than ordinary generic substitution, unless a newer formulation patent or a listed method-of-use patent creates a meaningful launch barrier. A definitive list of current challengers must be tied to a specific reference listed drug and current ANDA litigation docket. FDA approval records and district-court filings are the controlling sources.[3,5]

What generic entry risks exist for terbinafine hydrochloride?

Generic entry risk is high for conventional oral tablets and standard topical creams. A new branded product should assume rapid price competition unless it has one or more of the following:

• A protected delivery technology.
• A clinically validated reduction in treatment duration.
• A substantially improved nail-delivery profile.
• Superior tolerability.
• Pediatric palatability or dosing convenience.
• A device or packaging advantage that supports adherence.
• A combination product with a defensible clinical rationale.

The greatest risk is substitution by a lower-cost generic with equivalent active-ingredient strength and acceptable product performance. Topical products may have more commercial segmentation because vehicle feel, drying time, odor, applicator design and packaging influence consumer choice.

How does terbinafine hydrochloride compare with competing antifungal products?

Product or class	Main advantage	Main limitation	Excipient opportunity
Terbinafine topical	Strong dermatophyte activity and short topical regimens	Limited nail penetration; irritation possible	Film-forming and nail-delivery vehicles
Terbinafine oral	Effective for onychomycosis and extensive disease	Hepatic monitoring and drug interactions	Dose-flexible tablets or pediatric granules
Clotrimazole topical	Broad consumer familiarity and low cost	Often requires longer treatment	Convenience and sensory improvements
Ketoconazole topical	Useful for selected fungal and seborrheic conditions	Resistance and regulatory limitations in some uses	Mild emulsions and combination products
Ciclopirox topical	Nail-lacquer positioning	Long treatment duration and adherence burden	Improved film removal, penetration and dosing
Efinaconazole topical	Nail-specific product positioning	High cost and long treatment course	Solubilized low-viscosity systems and optimized applicators
Itraconazole oral	Broad antifungal spectrum	Drug interactions and pharmacokinetic variability	Dissolution and absorption enhancement

Terbinafine’s strongest commercial position is in dermatophyte infections where rapid fungicidal activity and established clinical use matter. Its largest formulation gap is the nail plate.

What are the best commercial opportunities for terbinafine hydrochloride?

Premium topical products

A premium topical product can compete on drying time, non-greasy feel, low irritation and reduced application mess. This opportunity is more realistic than attempting to create a premium conventional tablet.

Nail-focused delivery

A terbinafine nail product could compete with ciclopirox and efinaconazole if it delivers adequate drug through the nail while reducing treatment duration or application frequency. The development program would require nail penetration studies, mycological cure endpoints, long-term follow-up and robust vehicle stability.

Pediatric products

Terbinafine oral granules, dispersible tablets or sprinkle formulations could target children with tinea capitis. Excipients must address taste masking, dose uniformity, reconstitution or sprinkling performance and age-appropriate safety. Avoiding excessive sugar, allergenic excipients and high ethanol content can improve positioning.

Combination products

Potential combinations include terbinafine with keratolytics, anti-inflammatory agents or antibacterial actives. The commercial rationale must be strong because combination products raise clinical, regulatory and IP complexity. A corticosteroid combination may improve short-term symptoms but can create safety and stewardship concerns.

Private-label and regional products

Mature terbinafine products are suitable for retail, pharmacy and private-label manufacturing. The primary levers are low-cost excipient sourcing, tube and pump selection, fill-weight control, regulatory dossiers and multi-country packaging.

Manufacturing and supply-chain advantages

The API is widely available, so manufacturing differentiation is more likely to come from:

• Continuous or high-throughput blending.
• Direct compression with tight content-uniformity control.
• Low-shear processing that limits active degradation.
• Improved tube filling and reduced topical-product waste.
• Moisture- and solvent-resistant packaging.
• Stable sourcing of pharmacopeial-grade excipients.

What regulatory issues affect terbinafine excipient strategy?

Excipients must be appropriate for the route, dose and patient population. For oral products, the formulation must meet dissolution, impurity, stability and bioequivalence requirements. For topical products, sponsors must control microbial quality, preservative effectiveness, active uniformity, rheology, phase separation and in-use stability.

FDA’s inactive-ingredient database can support early excipient screening, but prior use does not eliminate the need for product-specific safety and quality assessment.[6] The regulatory pathway also differs by dosage form:

• Oral generic tablets generally use ANDA-based development when sameness and bioequivalence requirements are met.
• New topical products may require a drug application or an applicable OTC monograph pathway.
• Novel nail-delivery systems may require clinical evidence beyond conventional generic expectations.
• Combination products may require separate efficacy and safety justification for each active ingredient.

What revenue exposure does terbinafine hydrochloride create?

Revenue exposure is concentrated in competitive, mature markets. Conventional oral tablets are vulnerable to generic price erosion, while topical products can preserve margin through branding, packaging and consumer differentiation.

A commercial model should separate:

1. Unit volume from price.
2. Prescription oral sales from OTC topical sales.
3. Standard creams from premium delivery systems.
4. API sales from finished-dose sales.
5. Domestic sales from regulated international markets.
6. Base products from patent-protected innovations.

The most defensible revenue opportunity is a differentiated topical or nail product with measurable clinical or adherence value. A conventional terbinafine tablet is more suitable for scale, low-cost manufacturing and portfolio completeness than for premium pricing.

Key Takeaways

• Terbinafine hydrochloride is a mature antifungal with high generic risk in conventional oral and topical formats.
• Tablet excipient strategy should prioritize dissolution, blend uniformity, mechanical strength and low manufacturing cost.
• Topical opportunity is concentrated in low-irritancy, fast-drying, high-residence and nail-delivery systems.
• The active ingredient itself provides limited modern exclusivity leverage; formulation, device, process and use claims are more commercially relevant.
• Pediatric dose flexibility and palatability offer a practical niche.
• Nail delivery has the highest potential value but also the greatest technical and clinical risk.
• Orange Book analysis must distinguish prescription oral products from nonprescription topical products.
• A premium product requires evidence of better penetration, tolerability, convenience, treatment duration or adherence.

FAQs

Can terbinafine hydrochloride be formulated as a sustained-release tablet?

Yes, but the commercial rationale is limited. Oral terbinafine already has a relatively long terminal half-life because of tissue distribution, so sustained release would need to demonstrate a meaningful benefit in exposure control, tolerability, adherence or dosing convenience.

Which excipient is most important for terbinafine tablet dissolution?

No single excipient determines performance. Wetting, particle size, disintegrant efficiency, lubricant level and manufacturing process collectively control dissolution. Excessive magnesium stearate or poor wetting can reduce performance.

Is terbinafine hydrochloride suitable for a transdermal patch?

A conventional systemic transdermal patch is technically challenging because the required delivery rate, skin tolerability and dose loading may be difficult to achieve. A local skin or nail film is more commercially plausible than systemic transdermal delivery.

Can terbinafine hydrochloride be combined with urea?

Urea can act as a humectant and keratolytic at higher concentrations, potentially improving access to thickened skin or nail. The combination requires evaluation of active stability, irritation, crystallization and product classification.

Does terbinafine hydrochloride have biosimilar risk?

No. Terbinafine hydrochloride is a small-molecule drug, not a biologic. Its competitive risk comes from generic drugs, authorized generics, OTC equivalents and reformulated products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2023). Terbinafine hydrochloride tablets: Prescribing information. FDA/DailyMed.

2. National Library of Medicine. (2024). DailyMed: Terbinafine hydrochloride product labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Drug approval package and exclusivity information. FDA, Center for Drug Evaluation and Research.

5. U.S. Courts. (2024). Patent litigation records involving abbreviated new drug applications. PACER and federal district court records.

6. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA, Center for Drug Evaluation and Research.